MEDIATOR INFORMATION NEWSROOM NEWS PRESS RELEASE INSIGHT CORPORATE PUBLISHING MEDICAL PUBLISHING TERMS OF USEDATA PRIVACYCOOKIE MANAGEMENTCONTACT USREPORT A SIDE EFFECT ©2020 SERVIER LABORATORIES We use cookies to improve your experience, produce audience statistics, offer you services tailored to your interests and provide features associated with social media. You can change your preferences at any time on the site. Accept all Change cookie settings Privacy policy

MEDIATOR INFORMATION OUR RESEARCH & DEVELOPMENT Accelerating therapeutic innovation CLAUDE BERTRAND, Executive Vice President Research & Development To achieve the objectives the Group has set for 2025, R&D has developed an initial three-year action plan that focuses on three core activities… READ MORE → Servier organizes its R&D in 4 therapeutic areas where it has extensive know-how and renowned expertise and in which there are high unmet patient needs: oncology, neuroscience, immuno-inflammatory diseases, as well as cardiovascular and metabolic diseases. R&D KEY FIGURES 23 % of revenue from brand-name medicines invested in R&D in 2019/2020 50 % of the Servier global R&D budget* dedicated to researching cancer treatments * brand-name activity + than 40 active alliances worldwide SYMPHOGEN FOCUS, SUBSIDIARY OF THE SERVIER GROUP Founded in 2000 and based in Denmark, Symphogen is a biotech company that has developed an efficient discovery and research platform that can rapidly identify high quality monoclonal and bi-specific antibodies supported by early development capabilities with strong in vitro and in vivo capacities across oncology and immuno-oncology. Symphogen is organized as a combined project and line organization with various research, pre-clinical, CMC (Chemistry, Manufacturing and Control), clinical and regulatory departments. As part of the acquisition by Servier, Symphogen becomes the antibody center of excellence of the Group as its platform can deliver antibodies with unique functionalities providing best or first in class potential. READ MORE → Therapeutic areas See more Servier Paris-Saclay R&D Institute See more Clinical trials See more Our development portfolio See more Regulatory affairs See more Pharmacovigilance See more In this section Insight Understanding Companion Diagnostic Tests 24 / 11 / 2021 News World Pancreatic Cancer Day: Servier strives to make progress in cancer treatments 18 / 11 / 2021 News World Diabetes Day: promoting prevention, treatment, and care of diabetes 14 / 11 / 2021 TERMS OF USEDATA PRIVACYCOOKIE MANAGEMENTCONTACT USREPORT A SIDE EFFECT ©2020 SERVIER LABORATORIES